In a new study, published in the Feb. 28 online edition of The Lancet Infectious Diseases, authors estimate that between 10% and 15% of HIV patients in Europe and the United States are infected with a form of HIV that already has at least one drug-resistant mutation.
For the study, 10,056 HIV patients who were beginning combination antiretroviral therapy (cART) for the first time were categorized into three resistance categories: 9,102 patients (90.5%) had no transmitted drug-resistance (TDR); 475 patients (4.7%) had at least one mutation and were receiving fully active cART; and 479 patients (4.8%) had at least one mutation and were resistant to at least one prescribed drug.
Compared with patients without TDR, those with TDR and resistance to at least one prescribed drug were more than three times as likely to experience treatment failure, confirming "the need for at least three fully active antiretroviral drugs to optimize the virological response to a first-line regimen," the authors wrote.
However, the risk of treatment failure was not significantly different between patients without TDR and those with TDR taking a fully active cART regimen containing drugs not compromised by resistance. Read the abstract:
http://www.unboundmedicine.com/medline/ebm/record/21354861/abstract/Effect_of_transmitted_drug_resistance_on_virological_and_immunological_response_to_initial_combination_antiretroviral_therapy_for_HIV__EuroCoord_CHAIN_joint_project_:_a_European_multicohort_study_?source=govdelivery
e-HAP provides the latest Web site updates, as well as information on CDC’s HIV/AIDS prevention science, programs and policies.
e-HAP | CDC HIV/AIDS
.png)
No hay comentarios:
Publicar un comentario